Home
University of Bergen
Yaping Hua's picture

Yaping Hua

Department of Clinical Science
  • E-mailyaping.hua@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2023). GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Frontiers in Immunology. 15 pages.
  • Show author(s) (2022). Proteasome‐mediated regulation of GATA2 expression and androgen receptor transcription in benign prostate epithelial cells. Biomedicines. 14 pages.
  • Show author(s) (2022). Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain. Frontiers in Pharmacology. 15 pages.
  • Show author(s) (2018). Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain. Pharmacology Research & Perspectives. 1-15.
  • Show author(s) (2017). An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. PLOS ONE. 1-20.
  • Show author(s) (2016). Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer. 15 pages.
  • Show author(s) (2013). Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Research. 7090-7100.
Academic chapter/article/Conference paper
  • Show author(s) (2017). Models of Tumor Progression in Prostate Cancer. 16 pages.
Poster
  • Show author(s) (2022). Robust production of potent dendritic cells for cancer immunotherapy.
  • Show author(s) (2022). Robust and potent dendritic cells for cancer immunotherapy.
  • Show author(s) (2022). Novel STAT3 inhibitors targeting the STAT3 dimerization.
  • Show author(s) (2022). Novel STAT3 inhibitors targeting the STAT3 dimerization.
  • Show author(s) (2022). FLT3L and GM-CSF improve conventional dendritic cell viability and function.
  • Show author(s) (2020). Novel STAT3 inhibitors targeting STAT3 dimerization by binding to STAT3 SH2 domain.
  • Show author(s) (2013). Reactive oxygen species induce prostate cancer cells via activation of the IL6/STAT3 pathway. Abstract 304.
Chapter
  • Show author(s) (2022). Models of Tumor Progression in Prostate Cancer. 453-466. In:
    • Show author(s) (2022). Biomarkers of the Tumor Microenvironment. Springer.

More information in national current research information system (CRIStin)